Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DermTech, Inc.DMTK · Entity 89998 | Director | June 01, 2023 | June 05, 2023 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | October 01, 2026 | October 03, 2026 |
| Nautilus Biotechnology, Inc.NAUT · Entity 6679 | Director | June 18, 2026 | June 22, 2026 |
| Talis Biomedical CorpTLIS · Entity 87664 | Director | June 09, 2023 | June 12, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DermTech, Inc.
Report date June 01, 2023 · Filed June 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 158,215 |
Reported balance
After 2023-06-01 transaction · row 1
1 source rowRow 1 · 2023-06-01 · Grant · Acquired 35,714 · Balance 158,215 F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. Pursuant to the issuer's Second Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer the receipt of the shares underlying any vested restricted stock units to January 2, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. Pursuant to the issuer's Second Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer the receipt of the shares underlying any vested restricted stock units to January 2, 2025.
HALOZYME THERAPEUTICS, INC.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,609 |
Ending reported balance
After 2026-10-01 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-10-01 · Sale · Disposed 730 · Balance 58,109 F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.930 to $107.660. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-10-01 · Sale · Disposed 3,300 · Balance 54,809 F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-10-01 · Sale · Disposed 1,100 · Balance 53,709 F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.040 to $109.970. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-10-01 · Sale · Disposed 100 · Balance 53,609 F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1.
F2: Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.930 to $107.660. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.040 to $109.970. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Nautilus Biotechnology, Inc.
Report date June 18, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.28 · Expires 2036-06-18 | Direct | 45,000 |
Reported balance
After 2026-06-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-18 · Grant · Acquired 45,000 · Balance 45,000 F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).
Talis Biomedical Corp
Report date June 09, 2023 · Filed June 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-06-09 | Direct | 95,000 |
Reported balance
After 2023-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-09 · Grant · Acquired 95,000 · Balance 95,000 F1: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 100 | $110.04 | $11,004.00 |
DisclosureSEC source: 0001159036-26-000133 · wk-form4_1790973495.xml · nonDerivative · entry 4 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,609 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 1,100 | $109.57 | $120,525.90 |
DisclosureSEC source: 0001159036-26-000133 · wk-form4_1790973495.xml · nonDerivative · entry 3 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,709 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $109.040 to $109.970. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 3,300 | $108.45 | $357,898.20 |
DisclosureSEC source: 0001159036-26-000133 · wk-form4_1790973495.xml · nonDerivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,809 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.990 to $108.930. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| October 01, 2026 Filed Oct 3, 2026 00:38 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 730 | $107.17 | $78,232.64 |
DisclosureSEC source: 0001159036-26-000133 · wk-form4_1790973495.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,109 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.930 to $107.660. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 16, 2026 Filed Sep 17, 2026 21:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,000 | $108.99 | $435,964.00 |
DisclosureSEC source: 0001159036-26-000123 · wk-form4_1789679983.xml · nonDerivative · entry 4 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,839 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. F5 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $108.605 to $109.460. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 16, 2026 Filed Sep 17, 2026 21:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 8,896 | $108.04 | $961,123.84 |
DisclosureSEC source: 0001159036-26-000123 · wk-form4_1789679983.xml · nonDerivative · entry 3 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,839 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. F4 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $107.600 to $108.450. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 16, 2026 Filed Sep 17, 2026 21:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 3,000 | $106.83 | $320,484.00 |
DisclosureSEC source: 0001159036-26-000123 · wk-form4_1789679983.xml · nonDerivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,735 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $106.580 to $107.310. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| September 16, 2026 Filed Sep 17, 2026 21:19 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 3,100 | $106.13 | $329,009.20 |
DisclosureSEC source: 0001159036-26-000123 · wk-form4_1789679983.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,735 F1 · kind: The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on June 15, 2026 in accordance with Rule 10b5-1. F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $105.550 to $106.540. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 18, 2026 Filed Jun 22, 2026 20:14 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $2.28 | $0.00 |
DisclosureSEC source: 0001543792-26-000002 · wk-form4_1782159249.xml · derivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2036-06-18 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). Read SEC document |
| May 05, 2026 Filed May 7, 2026 23:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 6,040 | $0.00 Strike: $65.87 | $0.00 |
DisclosureSEC source: 0001159036-26-000064 · wk-form4_1778195074.xml · derivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,040 Underlying: Common Stock · 6,040 shares Expires 2036-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2026 Filed May 7, 2026 23:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 3,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000064 · wk-form4_1778195074.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,835 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 20:37 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.70 | $0.00 |
DisclosureSEC source: 0001808805-25-000063 · wk-form4_1750883840.xml · derivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 5,750 | $0.00 Strike: $60.03 | $0.00 |
DisclosureSEC source: 0001415889-25-011777 · form4-05022025_080510.xml · derivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2035-05-01 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 4,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011777 · form4-05022025_080510.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,039 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person following completion of service as a director. Read SEC document |
| August 14, 2024 Filed Aug 14, 2024 20:57 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 9,881 | $57.70 | $570,133.70 |
DisclosureSEC source: 0001415889-24-021305 · form4-08142024_080823.xml · nonDerivative · entry 3 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,874 F2 · balance_after: Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director. Read SEC document |
| August 13, 2024 Filed Aug 14, 2024 20:57 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $56.19 | $561,930.00 |
DisclosureSEC source: 0001415889-24-021305 · form4-08142024_080823.xml · nonDerivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,755 F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.058 to $56.26. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2 · balance_after: Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 20:57 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $55.72 | $557,230.00 |
DisclosureSEC source: 0001415889-24-021305 · form4-08142024_080823.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,755 F1 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.70 to $55.825. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2 · balance_after: Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are scheduled to be released to the reporting person following completion of service as a director. Read SEC document |
| June 14, 2024 Filed Jun 17, 2024 21:03 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $2.56 | $0.00 |
DisclosureSEC source: 0001808805-24-000045 · wk-form4_1718658225.xml · derivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-14 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $50.62 | $506,190.00 |
DisclosureSEC source: 0001415889-24-016672 · form4-06132024_080638.xml · nonDerivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,755 F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.50 to $50.935. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2 · balance_after: Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 20:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $50.01 | $500,110.00 |
DisclosureSEC source: 0001415889-24-016672 · form4-06132024_080638.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,755 F1 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $50.00 to $50.21. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F2 · balance_after: Includes 20,722 stock units that are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 8,804 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0001415889-24-011705 · form4-04292024_100445.xml · derivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,804 Underlying: Common Stock · 8,804 shares Expires 2034-04-25 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 22:11 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 6,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011705 · form4-04292024_100445.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,755 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 23:52 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001808805-23-000062 · wf-form4_168695955711451.xml · derivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). Read SEC document |
| June 09, 2023 Filed Jun 12, 2023 21:28 UTC | Talis Biomedical Corp TLIS · Entity 87664 | GrantStock option (right to buy) · Derivative | 95,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001209191-23-036403 · doc4.xml · derivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2033-06-09 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 22:20 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 35,714 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034582 · doc4.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,215 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. Pursuant to the issuer's Second Amended and Restated Non-Employee Director Compensation Policy, the reporting person elected to defer the receipt of the shares underlying any vested restricted stock units to January 2, 2025. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 11,371 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007694 · form4-05092023_100504.xml · derivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,371 Underlying: Common Stock · 11,371 shares Expires 2033-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:27 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007694 · form4-05092023_100504.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,254 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document |
| December 06, 2022 Filed Dec 7, 2022 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $56.12 | $561,180.00 |
DisclosureSEC source: 0001415889-22-012142 · form4-12072022_121235.xml · nonDerivative · entry 3 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,189 F3 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $56.10 to $56.19. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 05, 2022 Filed Dec 7, 2022 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $55.74 | $557,370.00 |
DisclosureSEC source: 0001415889-22-012142 · form4-12072022_121235.xml · nonDerivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,189 F2 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $55.70 to $55.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 02, 2022 Filed Dec 7, 2022 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $58.80 | $588,000.00 |
DisclosureSEC source: 0001415889-22-012142 · form4-12072022_121235.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,189 F1 · price: Represents a weighted average sales price per share. The shares were sold at prices ranging from $58.80 to $58.83. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 00:04 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 86,467 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0001808805-22-000071 · wf-form4_165542423007735.xml · derivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,467 Underlying: Common Stock · 86,467 shares Expires 2032-06-15 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month). Read SEC document |
| June 10, 2022 Filed Jun 13, 2022 21:41 UTC | Talis Biomedical Corp TLIS · Entity 87664 | GrantStock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036425 · doc4.xml · derivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 95,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: 1/12th of the shares subject to the option shall vest monthly over one year from the vesting commencement date. Read SEC document |
| May 26, 2022 Filed Jun 1, 2022 00:11 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 26,480 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032989 · doc4.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,501 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on May 26, 2023. Read SEC document |
| May 05, 2022 Filed May 7, 2022 00:07 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units | 6,206 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002912 · edgar.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,189 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 02:41 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 10,000 | $4.45 | $44,493.00 |
DisclosureSEC source: 0001808805-21-000026 · wf-form4_163841284890930.xml · nonDerivative · entry 4 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 02:41 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 10,000 | $4.46 | $44,612.00 |
DisclosureSEC source: 0001808805-21-000026 · wf-form4_163841284890930.xml · nonDerivative · entry 3 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 02:41 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 10,000 | $4.50 | $45,000.00 |
DisclosureSEC source: 0001808805-21-000026 · wf-form4_163841284890930.xml · nonDerivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 02:41 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 20,000 | $4.57 | $91,400.00 |
DisclosureSEC source: 0001808805-21-000026 · wf-form4_163841284890930.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Read SEC document |
| May 26, 2021 Filed May 29, 2021 00:19 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 4,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036712 · doc4.xml · nonDerivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,021 F2 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest, and the shares underlying the restricted stock units shall be released to the reporting person, on January 1, 2023, subject to the reporting person's continued service. Read SEC document |
| May 26, 2021 Filed May 29, 2021 00:19 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 4,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036712 · doc4.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,360 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. The restricted stock units shall vest in four equal quarterly installments over the one-year period following the grant date, subject to the reporting person's continued service. The shares underlying any vested restricted stock units shall be released to the reporting person on May 26, 2022. Read SEC document |
| May 05, 2021 Filed May 7, 2021 00:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units | 5,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-004974 · edgar.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,983 F1 · shares: Represents annual restricted stock unit grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2022 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 23:13 UTC | Talis Biomedical Corp TLIS · Entity 87664 | PurchaseCommon Stock | 62,500 | $16.00 | $1,000,000.00 |
DisclosureSEC source: 0001209191-21-012515 · doc4.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,500 Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:21 UTC | DermTech, Inc. DMTK · Entity 89998 | PurchaseCommon Stock | 33,898 | $29.50 | $999,991.00 |
DisclosureSEC source: 0001209191-21-003423 · doc4.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,863 F1 · shares: The securities were purchased by the reporting person in an underwritten public offering completed by the Issuer on January 11, 2021. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:19 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037920 · doc4.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,965 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's 2020 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. All of the restricted stock units shall vest in a single installment on June 17, 2021, subject to the reporting person's continued service through the earlier to occur of (i) June 17, 2021 or (ii) the date of the issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| April 30, 2020 Filed May 1, 2020 23:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock | 8,829 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-005382 · edgar.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,753 F1 · shares: Represents annual restricted stock grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 30, 2021 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:24 UTC | DermTech, Inc. DMTK · Entity 89998 | Exercise / conversionStock Option (right to buy) · Derivative | 9,702 | $0.00 Strike: $6.94 | $0.00 |
DisclosureSEC source: 0001209191-20-026533 · doc4.xml · derivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,702 shares Expires 2026-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| April 29, 2020 Filed May 1, 2020 20:24 UTC | DermTech, Inc. DMTK · Entity 89998 | Exercise / conversionCommon Stock | 9,702 | $6.94 | $67,331.88 |
DisclosureSEC source: 0001209191-20-026533 · doc4.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 30, 2020 Filed Feb 3, 2020 21:15 UTC | DermTech, Inc. DMTK · Entity 89998 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-005995 · doc4.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,263 F1 · shares: The securities awarded are in the form of restricted stock units issued pursuant to the issuer's Amended and Restated 2010 Stock Plan. Each restricted stock unit represents a contingent right to receive one share of issuer common stock. Subject to the reporting person's continued service, all of the restricted stock units shall vest in a single installment on the date of the 2020 annual meeting of the stockholders of the issuer. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:10 UTC | DermTech, Inc. DMTK · Entity 89998 | Exercise / conversionRestricted Stock Units · Derivative | 15,994 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-000821 · doc4.xml · derivative · entry 2 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,994 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares of Issuer common stock underlying these restricted stock units have fully vested and were released to the reporting person on December 31, 2019. F2 · derivative.expiration_date: The shares of Issuer common stock underlying these restricted stock units have fully vested and were released to the reporting person on December 31, 2019. Read SEC document |
| December 31, 2019 Filed Jan 3, 2020 21:10 UTC | DermTech, Inc. DMTK · Entity 89998 | Exercise / conversionCommon Stock | 15,994 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-000821 · doc4.xml · nonDerivative · entry 1 Posard Matthew L. · CIK 0001543792 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,263 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.